サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1383695

子宮がん治療・診断市場- 世界の産業規模、動向、機会、予測、2018年～2028年、がんタイプ別、治療別、診断別、地域別、競合

Uterine Cancer Therapeutics & Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Cancer Type, by Therapeutics, by Diagnostics, By Region, and Competition
出版日: | 発行: TechSci Research | ページ情報: 英文 175 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

子宮がん治療・診断市場- 世界の産業規模、動向、機会、予測、2018年～2028年、がんタイプ別、治療別、診断別、地域別、競合
出版日: 2023年10月03日
発行: TechSci Research
ページ情報: 英文 175 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の子宮がん治療・診断市場は、予測期間中に目覚ましい成長を遂げると予測されています。

子宮体がんは、子宮内膜がんとしても知られ、子宮内膜と呼ばれる子宮の内側に発生するがんの一種です。子宮は女性の生殖器官であり、妊娠中に受精卵が着床し、発育中の胎児が成長する場所です。子宮体がんは、子宮内膜内で異常な細胞が制御不能に増殖することで発生します。子宮体がんは多くの場合、異常な膣出血、骨盤痛、排尿または排便習慣の変化などの症状を呈します。子宮体がんの危険因子としては、肥満、ホルモンバランスの乱れ、家族歴、リンチ症候群のような特定の遺伝的疾患が挙げられます。子宮体がんの診断には通常、病歴評価、身体診察、画像検査（経腟超音波検査、MRI検査、CT検査など）、組織生検（通常、子宮内膜生検または拡張掻爬術によって得られる）を組み合わせる。がんの病期分類は、がんの広がりの程度を判定し、治療方針を決定するのに役立ちます。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 子宮がん治療・診断の世界市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • がんタイプ別（子宮内膜腺がん、腺扁平上皮がん、漿液性乳頭がん、子宮肉腫）
    • 治療別（手術、免疫療法、放射線療法、化学療法、その他）
    • 診断別（生検、骨盤超音波、子宮鏡、拡張掻爬、CTスキャン）
    • 地域別
    • 企業別（2022年）
  • 市場マップ

第6章 アジア太平洋地域の子宮がん治療・診断市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • がんタイプ別
    • 治療別
    • 診断別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • オーストラリア
    • 日本
    • 韓国

第7章 欧州の子宮がん治療・診断市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • がんタイプ別
    • 治療別
    • 診断別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • スペイン
    • イタリア
    • 英国

第8章 北米の子宮がん治療・診断市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • がんタイプ別
    • 治療別
    • 診断別
    • 国別
  • 北米国別分析
    • 米国
    • メキシコ
    • カナダ

第9章 南米の子宮がん治療・診断市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • がんタイプ別
    • 治療別
    • 診断別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの子宮がん治療・診断市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • がんタイプ別
    • 治療別
    • 診断別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 世界の子宮がん治療・診断市場：SWOT分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 PESTLE分析

第16章 競合情勢

  • Ariad Pharmaceuticals, Inc.
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials（In case of listed companies）
    • Recent Developments
    • SWOT Analysis
  • Abbott Laboratories Inc.
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials（In case of listed companies）
    • Recent Developments
    • SWOT Analysis
  • Becton, Dickinson & Co.
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials（In case of listed companies）
    • Recent Developments
    • SWOT Analysis
  • GlaxoSmithKline Plc
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials（In case of listed companies）
    • Recent Developments
    • SWOT Analysis
  • Merck & Co., Inc.
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials（In case of listed companies）
    • Recent Developments
    • SWOT Analysis
  • Novartis AG
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials（In case of listed companies）
    • Recent Developments
    • SWOT Analysis
  • Sanofi SA
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials（In case of listed companies）
    • Recent Developments
    • SWOT Analysis
  • Siemens Healthcare Inc.
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials（In case of listed companies）
    • Recent Developments
    • SWOT Analysis
  • Roche Holding AG
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials（In case of listed companies）
    • Recent Developments
    • SWOT Analysis

第17章 戦略的提言

第18章 調査会社・免責事項

目次
Product Code: 17599

Global Uterine Cancer Therapeutics & Diagnostics Market is anticipated to witness an impressive growth in the forecast period. Uterine cancer, also known as endometrial cancer, is a type of cancer that originates in the lining of the uterus, called the endometrium. The uterus is a female reproductive organ where a fertilized egg implants and a developing fetus grows during pregnancy. Uterine cancer occurs when there is uncontrolled growth of abnormal cells within the endometrial lining. Uterine cancer often presents with symptoms such as abnormal vaginal bleeding, pelvic pain, and changes in urinary or bowel habits. The risk factors for uterine cancer include obesity, hormone imbalances, a family history of the disease, and certain genetic conditions like Lynch syndrome. Diagnosis of uterine cancer typically involves a combination of medical history evaluation, physical examination, imaging studies (such as transvaginal ultrasound, MRI, or CT scans), and tissue biopsy (usually obtained through endometrial biopsy or dilation and curettage). Staging of the cancer helps determine the extent of its spread and guides treatment decisions.

Treatment for uterine cancer varies depending on the stage, type, and individual patient factors but often includes surgery (such as hysterectomy), radiation therapy, chemotherapy, targeted therapy, and, in some cases, immunotherapy. Early detection and timely treatment can lead to favorable outcomes for many uterine cancer patients. Improved diagnostic techniques, including imaging modalities like MRI and CT scans, as well as molecular and genetic testing, enabled earlier and more accurate diagnosis of uterine cancer. Ongoing research and development efforts led to innovations in uterine cancer therapeutics. This included the development of targeted therapies, immunotherapies, and novel chemotherapeutic agents. The aging population, particularly in developed nations, contributed to a higher prevalence of uterine cancer. Older individuals are at higher risk for this type of cancer.

Key Market Drivers

Increasing Geriatric Population

Uterine cancer is more common in older women. As individuals age, their risk of developing uterine cancer increases, which leads to a higher demand for diagnostics and treatment. Older individuals may have a higher likelihood of being diagnosed with uterine cancer at an advanced stage due to factors such as delayed healthcare-seeking behavior or comorbidities. This underscores the need for effective diagnostics and therapies. Managing uterine cancer in older patients can be complex due to the presence of other age-related health conditions. This demographic requires specialized care and tailored treatment plans, driving demand for appropriate therapeutics. Advances in healthcare have led to increased life expectancy, resulting in a larger population of older adults. A longer lifespan means a higher likelihood of encountering age-related illnesses, including uterine cancer. Healthcare systems often implement cancer screening programs, including uterine cancer screenings, for older individuals. Regular screenings can lead to earlier diagnosis and treatment initiation.

In elderly patients, treatment decisions must consider not only the cancer but also the patient's overall health and potential treatment-related side effects. This necessitates a comprehensive approach to diagnostics and therapy. With the aging population contributing to a substantial portion of uterine cancer cases, there is a growing focus on studying the unique characteristics and treatment needs of older patients. Research in this area informs better diagnostics and therapeutic strategies. Advocacy groups for older adults often raise awareness about cancer risks and encourage screenings and early detection, contributing to increased demand for diagnostics. Efforts to improve healthcare access for older adults, including preventive and diagnostic services, play a crucial role in addressing the needs of this demographic. The pharmaceutical industry recognizes the growing demand for therapies tailored to older patients, leading to the development of drugs that consider age-related factors. This factor will help in the development of the Global Uterine Cancer Therapeutics & Diagnostics Market.

Technological Advancements

Liquid biopsies involve analyzing blood samples for circulating tumor DNA (ctDNA) or other biomarkers. These non-invasive tests can detect genetic mutations and monitor treatment response over time. Next-Generation Sequencing (NGS) allows for comprehensive genetic profiling of uterine cancer tumors. It identifies specific mutations and alterations, aiding in treatment selection, especially in advanced or recurrent cases. Molecular imaging techniques, such as positron emission tomography (PET), can provide valuable insights into the metabolic activity of uterine tumors. This helps in tumor characterization and staging. Improvements in imaging modalities, including magnetic resonance imaging (MRI) and computed tomography (CT), have led to better visualization of uterine tumors, helping in diagnosis and treatment planning. AI and machine learning algorithms are being used to analyze medical images and pathology slides. AI can aid in the early detection of uterine cancer, identify tumor characteristics, and assist pathologists in making more accurate diagnoses. Advanced ultrasound techniques provide three-dimensional and real-time four-dimensional images of uterine tumors, aiding in precise diagnosis and monitoring.

Advances in molecular biology have led to the development of targeted therapies that specifically target the molecular pathways involved in uterine cancer growth. Drugs like palbociclib and ribociclib inhibit cell cycle progression and have shown promise in treating advanced uterine cancer. Immunotherapy drugs, such as pembrolizumab and nivolumab, work by harnessing the patient's immune system to attack cancer cells. These treatments have shown effectiveness in some uterine cancer patients, particularly those with microsatellite instability-high (MSI-H) tumors. Technological advancements in minimally invasive surgery, including robotic-assisted procedures, have reduced surgical complications and recovery times for uterine cancer patients. Techniques like intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) allow for more precise and targeted radiation delivery, minimizing damage to surrounding healthy tissues. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a technology that involves delivering heated chemotherapy directly to the abdominal cavity during surgery. It is used for advanced uterine cancer cases to improve treatment outcomes. Genetic profiling of tumors allows for personalized treatment plans tailored to the individual patient's cancer characteristics. This approach maximizes treatment effectiveness while minimizing side effects. Advanced drug delivery systems, such as nanoparticles and liposomes, enhance the targeted delivery of chemotherapy drugs to uterine tumors, improving their efficacy while reducing systemic side effects. Technologies that facilitate patient enrollment and monitoring in clinical trials have accelerated the development and testing of innovative uterine cancer therapies. This factor will pace up the demand of the Global Uterine Cancer Therapeutics & Diagnostics Market.

Rising Uterine Cancer Incidence

As the incidence of uterine cancer increases, there are more individuals diagnosed with this disease. This naturally leads to a greater demand for diagnostics to confirm the presence of cancer and determine its characteristics. While the incidence is rising, there is also a growing emphasis on early detection and screening programs. As a result, more individuals are being diagnosed at an earlier stage of the disease, necessitating timely diagnostics and treatment. Treating uterine cancer often involves a combination of surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, depending on the stage and type of cancer. As the number of cases increases, so does the demand for various therapeutic options. Advances in diagnostics and molecular profiling allow for personalized treatment plans tailored to the specific characteristics of a patient's tumor. This personalized approach is increasingly important as the incidence rises. An increased incidence of uterine cancer provides a larger pool of patients for clinical trials, which are essential for testing new therapeutics and diagnostics. This, in turn, contributes to the development of more advanced and effective treatments.

The growing incidence of uterine cancer often attracts more research funding and attention from pharmaceutical companies and researchers, leading to innovations in therapeutics and diagnostics. A higher incidence of uterine cancer often leads to increased public awareness of the disease and its risk factors. This heightened awareness can encourage individuals to seek medical attention and screening, driving demand for diagnostics. The increasing incidence may prompt healthcare systems to improve their infrastructure, including diagnostic facilities and cancer treatment centers, to accommodate the growing number of patients. With more cases of uterine cancer, there may be increased efforts to ensure health insurance coverage for cancer diagnostics and treatments, making these services more accessible to patients. Patient advocacy groups and organizations dedicated to uterine cancer often work to raise awareness and advocate for better access to diagnostics and treatments for those affected by the disease. This factor will accelerate the demand of the Global Uterine Cancer Therapeutics & Diagnostics Market.

Key Market Challenges

Comorbidities and Multidisciplinary Care

Many uterine cancer patients have comorbid conditions, such as diabetes, hypertension, heart disease, or obesity. Managing uterine cancer alongside these comorbidities can complicate treatment decisions. Healthcare providers must weigh the benefits of aggressive cancer treatment against the potential risks and interactions with existing health conditions and medications. Comorbidities can affect a patient's ability to tolerate cancer treatments, such as surgery, chemotherapy, or radiation therapy. For example, individuals with heart disease may be at increased risk during surgery or may not tolerate certain chemotherapy regimens. Patients with multiple health conditions often take multiple medications. The potential for drug interactions between cancer therapies and medications for comorbidities must be carefully managed to avoid adverse effects. Due to the complexity of managing uterine cancer in patients with comorbidities, a multidisciplinary approach involving oncologists, surgeons, cardiologists, endocrinologists, and other specialists is often necessary. Coordinating care and communication among these specialists can be challenging. Each patient's case is unique, requiring individualized treatment plans that consider both the cancer and comorbidities. This necessitates close collaboration among healthcare providers. Determining the optimal sequencing of cancer treatments and interventions for comorbidities is crucial. For example, deciding whether to address heart disease or uterine cancer first can impact treatment outcomes.

Cost of Treatment

Uterine cancer treatment often involves a combination of modalities, including surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Each of these treatments comes with its own costs, and the total expense can be substantial. Advancements in cancer therapies, such as targeted therapies and immunotherapies, tend to be expensive. These treatments are often tailored to individual patients and can be cost-prohibitive for some. Diagnostic tests and imaging, including MRI, CT scans, PET scans, and genetic profiling, can be expensive. Multiple diagnostic tests may be needed for accurate staging and treatment planning. Chemotherapy drugs, immunotherapy drugs, and targeted therapies can be costly. Some patients require these medications over an extended period, which can result in significant expenses. Surgical procedures, including minimally invasive and robotic-assisted surgeries, can be expensive, especially if complications arise. The need for a multidisciplinary care team involving oncologists, surgeons, radiologists, and other specialists can lead to increased consultation and treatment costs. Managing side effects of treatment, such as nausea, anemia, and fatigue, often requires additional medications and medical interventions.

Key Market Trends

Precision Medicine

Advances in genetic testing allowed for the comprehensive profiling of uterine cancer tumors. This profiling identified specific genetic mutations and alterations that drive cancer growth. Oncologists could use this information to select targeted therapies that were more likely to be effective for individual patients. Researchers were identifying and validating specific biomarkers associated with uterine cancer. These biomarkers could be used for early detection, prognosis assessment, and treatment decision-making. Precision medicine guided treatment decisions based on the molecular characteristics of a patient's tumor. This approach minimized the use of one-size-fits-all treatments and aimed to improve treatment efficacy while reducing side effects. Immunotherapy drugs, which stimulate the patient's immune system to target cancer cells, were being explored as part of precision medicine approaches for uterine cancer. Some patients with specific molecular profiles responded well to immunotherapy. Precision medicine was driving the design of clinical trials that focused on specific genetic subtypes of uterine cancer. These trials aimed to test new therapies and treatment combinations tailored to the molecular profiles of patients. Precision medicine also played a role in assessing a patient's risk of developing uterine cancer based on their genetic and environmental factors. This could inform prevention and early detection strategies.

Segmental Insights

Cancer Type Insights

In 2022, the Global Uterine Cancer Therapeutics & Diagnostics Market largest share was held by Endometrial Adenocarcinoma segment and is predicted to continue expanding over the coming years. Endometrial adenocarcinoma is the most common type of uterine cancer, accounting for a substantial portion of uterine cancer cases. This high incidence can lead to a greater emphasis on research, diagnostics, and therapeutics specific to this subtype. Endometrial adenocarcinoma has distinct molecular and histological characteristics that may require tailored treatment approaches. Understanding these specific characteristics is essential for developing effective therapies and diagnostics. Early detection is critical for improving the prognosis of uterine cancer, and endometrial adenocarcinoma is often diagnosed at an earlier stage compared to other subtypes. This may result in a greater focus on screening and diagnostics for this subtype. Clinical trials and research efforts often focus on specific cancer subtypes, including endometrial adenocarcinoma. Advances in treatment options, including targeted therapies and immunotherapies, may have been more prominent in this segment.

Therapeutics Insights

In 2022, the Global Uterine Cancer Therapeutics & Diagnostics Market by chemotherapy segment and is predicted to continue expanding over the coming years. Chemotherapy has long been a standard treatment for uterine cancer, especially for patients with advanced or recurrent disease. It is often used in combination with surgery or radiation therapy to improve treatment outcomes. Chemotherapy can be used in various stages of uterine cancer, from early-stage to advanced-stage disease. This versatility makes it a commonly prescribed treatment option. In some cases, chemotherapy is combined with other treatments, such as radiation therapy or targeted therapy, to enhance the overall effectiveness of treatment. Uterine cancer can spread beyond the uterus, making it necessary to target cancer cells that may have travelled to other parts of the body. Chemotherapy is a systemic treatment that can reach cancer cells throughout the body.

Diagnostics Insights

In 2022, the Global Uterine Cancer Therapeutics & Diagnostics Market largest share was held by Biopsy segment in the forecast period and is predicted to continue expanding over the coming years. Biopsy is a crucial diagnostic tool for uterine cancer. It involves the removal of a tissue sample from the uterus or endometrium for examination under a microscope. This process is essential for confirming the presence of cancer, determining its type and stage, and guiding treatment decisions. Biopsy provides a definitive diagnosis of uterine cancer. It allows pathologists to examine the tissue sample for cancerous cells, identify the specific type of uterine cancer (e.g., endometrial carcinoma), and assess the extent of cancer invasion. The results of a uterine cancer biopsy help oncologists formulate an appropriate treatment plan. The type and stage of cancer identified through biopsy influence treatment decisions, whether it involves surgery, radiation therapy, chemotherapy, immunotherapy, or targeted therapies.

Regional Insights

The North America region dominates the Global Uterine Cancer Therapeutics & Diagnostics Market in 2022. North America, particularly the United States, has one of the highest healthcare spending rates in the world. This substantial investment in healthcare infrastructure and research and development contributes to advancements in uterine cancer therapeutics and diagnostics. The region boasts advanced healthcare facilities, medical technology, and a well-developed healthcare system. This allows for early detection, accurate diagnosis, and state-of-the-art treatment options for uterine cancer patients. North America is home to numerous pharmaceutical and biotechnology companies that invest heavily in cancer research, including uterine cancer. These companies develop innovative therapeutics and diagnostic tools for the market. The United States hosts a large number of clinical trials for various cancer types, including uterine cancer. Clinical trials are critical for testing new treatments and diagnostic methods, attracting patients from around the world.

Key Market Players

Ariad Pharmaceuticals, Inc.

Abbott Laboratories Inc.

Becton, Dickinson & Co.

GlaxoSmithKline Plc

Merck & Co., Inc.

Novartis AG

Sanofi SA

Siemens Healthcare Inc.

Roche Holding AG

Report Scope:

In this report, the Global Uterine Cancer Therapeutics & Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Uterine Cancer Therapeutics & Diagnostics Market, By Cancer Type:

  • Endometrial Adenocarcinoma
  • Adenosquamous Carcinoma
  • Papillary Serous Carcinoma
  • Uterine Sarcoma

Uterine Cancer Therapeutics & Diagnostics Market, By Therapeutics:

  • Surgery
  • Immunotherapy
  • Radiation Therapy
  • Chemotherapy
  • others

Uterine Cancer Therapeutics & Diagnostics Market, By Diagnostics:

  • Biopsy
  • Pelvic Ultrasound
  • Hysteroscopy
  • Dilation and Curettage
  • CT scan

Global Uterine Cancer Therapeutics & Diagnostics Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Uterine Cancer Therapeutics & Diagnostics Market.

Available Customizations:

  • Global Uterine Cancer Therapeutics & Diagnostics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Uterine Cancer Therapeutics & Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Cancer Type (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, Uterine Sarcoma)
    • 5.2.2. By Therapeutics (Surgery, Immunotherapy, Radiation Therapy, Chemotherapy, others)
    • 5.2.3. By Diagnostics (Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage, CT scan)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Market Map

6. Asia Pacific Uterine Cancer Therapeutics & Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Cancer Type
    • 6.2.2. By Therapeutics
    • 6.2.3. By Diagnostics
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Cancer Type
        • 6.3.1.2.2. By Therapeutics
        • 6.3.1.2.3. By Diagnostics
    • 6.3.2. India Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Cancer Type
        • 6.3.2.2.2. By Therapeutics
        • 6.3.2.2.3. By Diagnostics
    • 6.3.3. Australia Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Cancer Type
        • 6.3.3.2.2. By Therapeutics
        • 6.3.3.2.3. By Diagnostics
    • 6.3.4. Japan Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Cancer Type
        • 6.3.4.2.2. By Therapeutics
        • 6.3.4.2.3. By Diagnostics
    • 6.3.5. South Korea Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Cancer Type
        • 6.3.5.2.2. By Therapeutics
        • 6.3.5.2.3. By Diagnostics

7. Europe Uterine Cancer Therapeutics & Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Cancer Type
    • 7.2.2. By Therapeutics
    • 7.2.3. By Diagnostics
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Cancer Type
        • 7.3.1.2.2. By Therapeutics
        • 7.3.1.2.3. By Diagnostics
    • 7.3.2. Germany Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Cancer Type
        • 7.3.2.2.2. By Therapeutics
        • 7.3.2.2.3. By Diagnostics
    • 7.3.3. Spain Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Cancer Type
        • 7.3.3.2.2. By Therapeutics
        • 7.3.3.2.3. By Diagnostics
    • 7.3.4. Italy Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Cancer Type
        • 7.3.4.2.2. By Therapeutics
        • 7.3.4.2.3. By Diagnostics
    • 7.3.5. United Kingdom Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Cancer Type
        • 7.3.5.2.2. By Therapeutics
        • 7.3.5.2.3. By Diagnostics

8. North America Uterine Cancer Therapeutics & Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Cancer Type
    • 8.2.2. By Therapeutics
    • 8.2.3. By Diagnostics
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Cancer Type
        • 8.3.1.2.2. By Therapeutics
        • 8.3.1.2.3. By Diagnostics
    • 8.3.2. Mexico Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Cancer Type
        • 8.3.2.2.2. By Therapeutics
        • 8.3.2.2.3. By Diagnostics
    • 8.3.3. Canada Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Cancer Type
        • 8.3.3.2.2. By Therapeutics
        • 8.3.3.2.3. By Diagnostics

9. South America Uterine Cancer Therapeutics & Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Cancer Type
    • 9.2.2. By Therapeutics
    • 9.2.3. By Diagnostics
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Cancer Type
        • 9.3.1.2.2. By Therapeutics
        • 9.3.1.2.3. By Diagnostics
    • 9.3.2. Argentina Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Cancer Type
        • 9.3.2.2.2. By Therapeutics
        • 9.3.2.2.3. By Diagnostics
    • 9.3.3. Colombia Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Cancer Type
        • 9.3.3.2.2. By Therapeutics
        • 9.3.3.2.3. By Diagnostics

10. Middle East and Africa Uterine Cancer Therapeutics & Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Cancer Type
    • 10.2.2. By Therapeutics
    • 10.2.3. By Diagnostics
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Cancer Type
        • 10.3.1.2.2. By Therapeutics
        • 10.3.1.2.3. By Diagnostics
    • 10.3.2. Saudi Arabia Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Cancer Type
        • 10.3.2.2.2. By Therapeutics
        • 10.3.2.2.3. By Diagnostics
    • 10.3.3. UAE Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Cancer Type
        • 10.3.3.2.2. By Therapeutics
        • 10.3.3.2.3. By Diagnostics

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Uterine Cancer Therapeutics & Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Ariad Pharmaceuticals, Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Abbott Laboratories Inc.
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Becton, Dickinson & Co.
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. GlaxoSmithKline Plc
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. Merck & Co., Inc.
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. Novartis AG
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. Sanofi SA
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. Siemens Healthcare Inc.
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Roche Holding AG
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer